When lysates were administered in combination with anti-CTLA-4 mAb in this study, not only were the abnormal changes in Treg and M2 cells in CRC models suppressed, but memory CD8 + T cell (CD8 + CD44 + CD62L + ) numbers were increased compared with that in response to single anti-CTLA-4 mAb agent treatment (p < 0.05) These findings suggest that combinatorial treatments may increase the accumulation of anti-tumor responses in tumor-draining mesenteric lymph nodes (Fig. 6). The gene discussed is CD8A; the disease is neoplasm.